2 Hrs
Source:
سرايا الإخبارية
Source: سرايا الإخبارية
2 Hrsسرايا الإخبارية
Source: سرايا الإخبارية
2 HrsReady to play
Ready to play
Phase III trials showed that the experimental drug retatrutide, developed by Eli Lilly and targeting three hormone receptors, led to average weight loss of 19.5% and 20.9% after 80 weeks at doses of 9 mg and 12 mg, respectively, among people with type 2 diabetes, compared with 9.4% with Ozempic. In a separate trial, average weight loss reached 25% at the 12 mg dose among people with obesity who did not have diabetes. The drug has not yet received regulatory approval, and the company plans to apply for U.S. approval in the first quarter of 2027. The most common side effects included nausea, diarrhea, constipation and vomiting, so it is not currently an available alternative to approved treatments.
Notice: This Is an AI-Generated Summary
Comments (0)